Sonnet BioTherapeutics Analyst Ratings
Sonnet BioTherapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/16/2023 | 2756.46% | Chardan Capital | $14 → $12 | Maintains | Buy |
| 06/26/2023 | 1494.86% | EF Hutton | → $6.7 | Reiterates | Buy → Buy |
| 05/25/2023 | 1494.86% | EF Hutton | → $6.7 | Assumes | → Buy |
| 05/11/2023 | 3232.54% | Chardan Capital | $17 → $14 | Maintains | Buy |
| 04/19/2023 | 1494.86% | EF Hutton | → $6.7 | Reiterates | → Buy |
| 04/19/2023 | 3946.66% | Chardan Capital | $22 → $17 | Maintains | Buy |
| 02/15/2023 | 1494.86% | EF Hutton | → $6.7 | Reiterates | → Buy |
| 12/19/2022 | 1494.86% | EF Hutton | → $6.7 | Initiates Coverage On | → Buy |
| 09/22/2022 | 5136.85% | Chardan Capital | $2 → $22 | Maintains | Buy |
| 08/16/2022 | 376.08% | Chardan Capital | $2.5 → $2 | Maintains | Buy |
| 02/09/2022 | 376.08% | BTIG | $5 → $2 | Maintains | Buy |
| 12/20/2021 | 495.1% | Chardan Capital | $8 → $2.5 | Maintains | Buy |
| 12/16/2021 | 376.08% | HC Wainwright & Co. | → $2 | Initiates Coverage On | → Buy |
| 09/15/2021 | 1090.19% | BTIG | → $5 | Initiates Coverage On | → Buy |
| 09/04/2020 | 1804.31% | Chardan Capital | $7 → $8 | Maintains | Buy |
| 06/05/2020 | 1566.27% | Chardan Capital | → $7 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 08/16/2023 | 2756.46% | 查丹資本 | 14 美元 → 12 美元 | 維護 | 購買 |
| 06/26/2023 | 1494.86% | EF Hutton | → 6.7 美元 | 重申 | 購買 → 購買 |
| 05/25/2023 | 1494.86% | EF Hutton | → 6.7 美元 | 假設 | → 購買 |
| 05/11/2023 | 3232.54% | 查丹資本 | 17 美元 → 14 美元 | 維護 | 購買 |
| 04/19/2023 | 1494.86% | EF Hutton | → 6.7 美元 | 重申 | → 購買 |
| 04/19/2023 | 3946.66% | 查丹資本 | 22 美元 → 17 美元 | 維護 | 購買 |
| 02/15/2023 | 1494.86% | EF Hutton | → 6.7 美元 | 重申 | → 購買 |
| 2022 年 12 月 19 日 | 1494.86% | EF Hutton | → 6.7 美元 | 啓動覆蓋開啓 | → 購買 |
| 2022 年 9 月 22 日 | 5136.85% | 查丹資本 | $2 → 22 美元 | 維護 | 購買 |
| 08/16/2022 | 376.08% | 查丹資本 | 2.5 美元 → 2 美元 | 維護 | 購買 |
| 02/09/2022 | 376.08% | BTIG | 5 美元 → 2 美元 | 維護 | 購買 |
| 2021 年 12 月 20 日 | 495.1% | 查丹資本 | 8 美元 → 2.5 美元 | 維護 | 購買 |
| 2021 年 12 月 16 日 | 376.08% | HC Wainwright & Co. | → 2 美元 | 啓動覆蓋開啓 | → 購買 |
| 2021 年 9 月 15 日 | 1090.19% | BTIG | → 5 美元 | 啓動覆蓋開啓 | → 購買 |
| 2020 年 4 月 9 日 | 1804.31% | 查丹資本 | 7 美元 → 8 美元 | 維護 | 購買 |
| 2020 年 5 月 6 日 | 1566.27% | 查丹資本 | → 7 美元 | 啓動覆蓋開啓 | → 購買 |
What is the target price for Sonnet BioTherapeutics (SONN)?
Sonnet Biotherapeutics（SONN）的目標價格是多少？
The latest price target for Sonnet BioTherapeutics (NASDAQ: SONN) was reported by Chardan Capital on August 16, 2023. The analyst firm set a price target for $12.00 expecting SONN to rise to within 12 months (a possible 2756.46% upside). 9 analyst firms have reported ratings in the last year.
Chardan Capital於2023年8月16日公佈了Sonnet Biotherapeutics（納斯達克股票代碼：SONN）的最新目標股價。這家分析公司將目標股價定爲12.00美元，預計SONN將在12個月內升至12個月內（可能上漲2756.46％）。去年有9家分析公司公佈了評級。
What is the most recent analyst rating for Sonnet BioTherapeutics (SONN)?
分析師對Sonnet Biotherapeutics（SONN）的最新評級是多少？
The latest analyst rating for Sonnet BioTherapeutics (NASDAQ: SONN) was provided by Chardan Capital, and Sonnet BioTherapeutics maintained their buy rating.
Sonnet BioTherapeutics（納斯達克股票代碼：SONN）的最新分析師評級由Chardan Capital提供，Sonnet BioTherapeutics維持買入評級。
When is the next analyst rating going to be posted or updated for Sonnet BioTherapeutics (SONN)?
Sonnet BioTherapeutics（SONN）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sonnet BioTherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sonnet BioTherapeutics was filed on August 16, 2023 so you should expect the next rating to be made available sometime around August 16, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Sonnet BioTherapeutics的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應該獲得4個評級。Sonnet BioTherapeutics的最後一次評級是在2023年8月16日提交的，因此你應該預計下一個評級將在2024年8月16日左右公佈。
Is the Analyst Rating Sonnet BioTherapeutics (SONN) correct?
分析師對 Sonnet BioTherapeutics (SONN) 的評級正確嗎？
While ratings are subjective and will change, the latest Sonnet BioTherapeutics (SONN) rating was a maintained with a price target of $14.00 to $12.00. The current price Sonnet BioTherapeutics (SONN) is trading at is $0.42, which is out of the analyst's predicted range.
儘管評級是主觀的，將會發生變化，但最新的Sonnet BioTherapeutics（SONN）評級維持不變，目標股價爲14.00美元至12.00美元。Sonnet BioTherapeutics（SONN）目前的交易價格爲0.42美元，超出了分析師的預測區間。
譯文內容由第三人軟體翻譯。